Takeda Pharmaceutica

4502
End-of-day quote Tokyo - 06/21
3778JPY
-1.18%
Income Statement Evolution
Annual Income Statement Data
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20192020
Sales2 097 2243 361 373
EBITDA477 415788 923
Operating profit (EBIT)-378 600
Pre-Tax Profit (EBT)94 896-248 694
Net income109 126-213 802
EPS ( JPY )114-136
Dividend per Share ( JPY )180180
Yield3,98%4,76%
Announcement Date05/14/2019
06:00am
-
Finances - Leverage
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20192020
Debt5 025 5824 512 627
Finance--
Operating income (EBITDA)477 415788 923
Leverage
(Debt/EBITDA)
10,5x5,72x
Capital Expenditure77 677229 777
Book Value Per Share (BVPS)3 319  JPY3 073  JPY
Cash Flow per Share342  JPY376  JPY
Announcement Date05/14/2019
06:00am
-
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 5 955 476 M JPY -
Entreprise Value (EV) 10 468 103 M JPY 10 004 101 M JPY
Valuation 2020e 2021e
P/E ratio (Price / EPS) 32,6x
Capitalization / Revenue 1,77x 1,74x
EV / Revenue 3,11x 2,92x
EV / EBITDA 13,3x 9,74x
Yield (DPS / Price) 4,76% 4,76%
Price to book (Price / BVPS) 1,23x 1,26x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 11,3% -
operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) -6,36% 4,94%
ROA (Net Profit / Asset) 1,58% 2,90%
ROE (Net Profit / Equities) -1,42% 6,43%
Rate of Dividend -132% 155%
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   6,84% 5,69%
Cash Flow / Sales 17,5% 24,2%
Capital Intensity (Assets / Sales) -4,03x 1,71x
Financial Leverage (Net Debt / EBITDA) 5,72x 3,94x
Price Earning Ratio
BNA & Dividende